GlassScriptPhysician profile
Farah M Smith
NPI 1447616461
$14,589.94
in general payments reported to CMS, 2019-2025
52 companies · $2,462 in 2025
The $2,462 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,870 · 2022: $2,969 · 2023: $3,453 · 2024: $2,835 · 2025: $2,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,510 · Education: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,510.04 |
| Education | $240.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,446.37 | 2021-2025 | |
| Novo Nordisk INC | $1,440.55 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,317.78 | 2021-2025 | |
| Corcept Therapeutics | $1,003.71 | 2023-2025 | Korlym |
| Glaxosmithkline, LLC. | $921.30 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $910.94 | 2021-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $742.94 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $709.98 | 2021-2024 | Veozah, Myrbetriq |
| Daiichi Sankyo INC. | $626.94 | 2021-2025 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $575.30 | 2021-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $521.67 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $341.33 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $268.09 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $261.02 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $233.79 | 2021 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $228.58 | 2021-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $206.94 | 2021-2025 | |
| Esperion Therapeutics, INC. | $191.74 | 2021-2023 | Nexletol |
| Sumitomo Pharma America, INC. | $180.95 | 2023-2024 | Gemtesa |
| Lilly USA, LLC | $155.15 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Electromed, INC. | $151.17 | 2022 | |
| Organogenesis INC. | $148.63 | 2023 | Puraply Antimicrobial, Puraply |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.65 | 2021-2025 | Jardiance, Synjardy |
| Nestle Healthcare Nutrition INC. | $132.85 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $128.55 | 2021 | |
| Urovant Sciences INC | $125.00 | 2022 | |
| Horizon Therapeutics Plc | $125.00 | 2023 | Krystexxa |
| Merck Sharp & Dohme LLC | $123.97 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Alkermes, INC. | $120.00 | 2024 | Lybalvi |
| Biohaven Pharmaceutical Holding Company LTD. | $107.34 | 2022 | |
| Abiomed | $97.92 | 2024 | Impella |
| Idorsia Pharmaceuticals US INC | $78.11 | 2022-2024 | Quviviq |
| Antares Pharma, INC. | $73.86 | 2022-2024 | Xyosted, Nocdurna, Tlando |
| Axsome Therapeutics, INC. | $71.06 | 2024-2025 | Auvelity |
| Dexcom, INC. | $59.25 | 2024-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $55.36 | 2024 | Rexulti |
| Exact Sciences Corporation | $51.90 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Opko Pharmaceuticals, LLC | $51.89 | 2023 | Rayaldee |
| Kowa Pharmaceuticals America, INC. | $51.45 | 2021-2022 | |
| Halozyme INC | $46.92 | 2023 | |
| Abbott Laboratories | $43.95 | 2022-2024 | Freestyle Libre 3 |
| Boston Scientific Corporation | $42.59 | 2022 | |
| Inspire Medical Systems, INC. | $40.96 | 2025 | Inspire |
| Sanofi Pasteur INC. | $39.39 | 2023 | |
| Aimmune Therapeutics, INC. | $37.90 | 2024-2025 | Zenpep |
| Amarin Pharma, INC. | $37.26 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $28.32 | 2024 | Eliquis, Camzyos |
| Takeda Pharmaceuticals U.S.A., INC. | $23.34 | 2021 | |
| Sanofi-Aventis U.S. LLC | $22.07 | 2025 | |
| Ardelyx, INC. | $19.74 | 2025 | Ibsrela |
| Philips North America LLC | $18.30 | 2024 | (Ak6) Vest Therapy |
| Regeneron Healthcare Solutions, INC. | $14.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farah Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.